Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Simultaneous determination of six flavonoids from Paulownia tomentosa flower extract in rat plasma by LC–MS/MS and its application to a pharmacokinetic study

Bin Dai, Zhiqiang Hu, Haiyan Li, Chong Yan, Liwei Zhang

A simple, rapid and sensitive liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was developed and validated for simultaneous determination of six components including apigenin, quercetin, apigenin-7-O-β-D-glucoside, quercetin-3-O-β-D-glucoside, 3’-methoxyluteolin-7-O-β-D-glucoside, and tricin-7-O-β-D-glucopyranoside in rat plasma using formononetin as the internal standard (IS). The plasma samples were pretreated by a one-step liquid–liquid extraction with dichloromethane. The chromatographic separation was carried out on a ZORBAX SB-Aq column with a gradient mobile phase consisting of acetonitrile and 2 mM aqueous ammonium acetate. All analytes and IS were quantitated through electrospray ionization in negative ion multiple reaction monitoring mode. The mass transitions were as follows: m/z 269.1 → 117.2 for apigenin, m/z 301.2 → 151.2 for quercetin, m/z 431.3 → 311.2 for apigenin-7-O-β-D-glucoside, m/z 463.2 → 300.2 for quercetin-3-O-β-D-glucoside, m/z 461.3 → 283.1 for 3’-methoxyluteolin-7-O-β-D-glucoside, m/z 491.3 → 313.1 for tricin-7-O-β-D-glucopyranoside, and m/z 267.2 → 252.2 for IS, respectively. All calibration curves exhibited good linearity with correlation coefficient (r) > 0.995. The intra-day and inter-day precisions (RSD) at the three QC levels were both less than 14.0% and the accuracies ranged from 89.8% to 113.8%. The extraction recoveries of six compounds ranged from 82.3% to 92.5%. The validated method was successfully applied to pharmacokinetic study of the six components in male rat plasma after oral administration of Paulownia tomentosa flower extract.

© 2014 Elsevier B.V. All rights reserved.

1. Introduction

Paulownia tomentosa Steud. is an important member of the Scrophulariaceae family that is widely used in traditional medicine for the treatment of infectious diseases, such as gonorrhea and erysipelas [1–3]. It has a wide spectrum of bioactivities, including neuroprotective, antioxidant, antibacterial, antiphlogistic, antiviral, and cytotoxic activities [4–9]. Therefore, determining the concentration of active components in P. tomentosa in biological samples for pharmacokinetic study is significant.

Flavonoids, lignans and iridoids are bioactive compounds of P. tomentosa [10–12]. Among these compounds, flavonoids are known because of their main bioactive constituents [13–15]. The flavonoids from P. tomentosa exhibited significant neuroprotective activity against glutamate-induced toxicity, and showed potent inhibition of human acetylcholinesterase and butyrylcholinesterase, which are linked to the amelioration of Alzheimer’s symptoms [16,10,4]. Moreover, the flavonoids of P. tomentosa displayed the inhibition of SARS-CoV papain-like protease that is an important antiviral target due to its key roles in SARS virus replication [6].

Several reports [17–19] have indicated that flavonoids, such as apigenin, quercetin, apigenin-7-O-β-D-glucoside, quercetin-3-O-β-D-glucoside, 3’-methoxyluteolin-7-O-β-D-glucoside, and tricin-7-O-β-D-glucopyranoside had played an important role in P. tomentosa or P. fortunei. Investigating the pharmacokinetics of these flavonoid components is necessary to better use P. tomentosa. Accordingly, a simple, sensitive, and robust liquid chromatography–tandem mass spectrometry (LC–MS/MS) is required to determine the flavonoids in the biological matrix. In this study, we developed a simple LC–MS/MS method

Keywords: LC–MS/MS Flavonoids Paulownia tomentosa Pharmacokinetic study

Article history:
Received 5 September 2014
Accepted 20 November 2014
Available online 3 December 2014

Department of Neurosurgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
School of Pharmacy, Guangdong Medical College, Dongguan 523808, China
Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing 100050, China

http://dx.doi.org/10.1016/j.chromb.2014.11.021
1570-0232/© 2014 Elsevier B.V. All rights reserved.
for the simultaneous determination of six flavonoids (apigenin, quercetin, apigenin-7-O-β-D-glucoside, quercetin-3-O-β-D-glucoside, 3’-methoxyluteolin-7-O-β-D-glucoside, and tricin-7-O-β-D-glucopyranoside) in rat plasma and their pharmacokinetics after oral administration of *P. tomentosa* flower extract.

2. Experimental

2.1. Materials and reagents

Standards of apigenin, quercetin, apigenin-7-O-β-D-glucoside, quercetin-3-O-β-D-glucoside, 3’-methoxyluteolin-7-O-β-D-glucoside, tricin-7-O-β-D-glucopyranoside, and formononetin (used as internal standard) were purchased from the CRM/RM Information Center of China (Beijing, China) (Fig. 1). HPLC-grade acetonitrile and methanol were purchased from Merck (Darmstadt, Germany). HPLC-grade water was obtained from a Milli-Q Water Purified System (Millipore, Bedford, MA, USA). Other reagents were of analytical grade.

2.2. Chromatographic conditions

The HPLC system consisted of an Agilent 1200 series (Agilent Technologies, Wilmington, DE, USA). Samples were separated on a ZORBAX SB-Aq (5 μm; 150 mm × 4.6 mm) column with a Security-Guard C18 (5 μm; 4.6 mm × 3 mm) column. A linear gradient elution of eluents A (2 mM aqueous ammonium acetate) and B (acetonitrile) was used for the separation, using a B gradient elution of 30% at 0–1 min, 30–70% at 2–5.5 min, and the reequilibration time of gradient elution was 5 min. The flow rate was set at 0.9 mL/min with split ratio of 2:1 (v/v), and the total run time was 10.5 min.

2.3. Mass spectrometric conditions

Ionization and detection of the six flavonoids and IS were carried out on an Agilent 6460 triple–quadrupole mass spectrometer (Agilent Technologies, Palo Alto, CA, USA) equipped with electrospray ionization (ESI) source and operating in negative ion mode. Data acquisition and quantification were performed by Agilent MassHunter workstation B.03.01 software (Agilent Technologies, USA). The drying gas temperature was maintained at 300 °C; the heater temperature was set at 350 °C at a sheath gas flow of 11 L/min; and the nebulizing gas (N2) pressure and capillary voltage were set at 45 psi and −4.0 kV. The dwell time was 50 ms for each compound, and mass analyzers Q1 and Q3 operated at unit mass resolution were used for each multiple reaction monitoring (MRM) transition. Compound-dependent parameters are listed in Table 1.

2.4. Preparation of *P. tomentosa* flower extract

Flowers were collected in Anhui, China, in April 2013, and identified by one of us (Prof. Chong Yan) as *P. tomentosa* flowers. A

![Fig. 1. The chemical structures of six flavonoids.](image-url)
voucher specimen (No. 201304YC) was deposited in the Chinese medicine specimens room, Guangdong Medical College (Dongguan, China). P. tomentosa flower extract (20 g) was soaked twice for 1 h in 70% ethanol (400 mL) at 80 °C [20,21]. The extracted solution obtained by filtration was concentrated under reduced pressure and used as samples for animal studies. To calculate the administered dose, we quantitatively determined the contents of the six constituents in the P. tomentosa extract through an external standard method using the same chromatography conditions previously described. The results showed that the concentrations of apigenin, quercetin, apigenin-7-O-β-d-glucoside, quercetin-3-O-β-d-glucoside, 3′-methoxyluteolin-7-O-β-d-glucoside, and tricin-7-O-β-d-glucopyranoside in the extract were 0.063, 0.101, 0.033, 0.048, 0.231, and 0.167 mg/mL, respectively.

2.5. Preparation of standard and quality control (QC) samples

Mixed stock solutions containing above six standards were prepared in methanol with a final concentration of 0.513 mg/mL for apigenin, 0.421 mg/mL for quercetin, 0.381 mg/mL for apigenin-7-O-β-d-glucoside, 0.320 mg/mL for quercetin-3-O-β-d-glucoside, 0.513 mg/mL for 3′-methoxyluteolin-7-O-β-d-glucoside, and 0.602 mg/mL for tricin-7-O-β-d-glucopyranoside, respectively. The mixture stock solution was serially diluted with a mixture of methanol–water (50:50, v/v) to provide working standard solutions of desired concentrations. The IS stock solution of 1.00 mg/mL was prepared in methanol. The IS working solution (100 ng/mL) was prepared by diluting the stock solution with methanol–water (50:50, v/v).

Plasma samples of standard calibration curves were prepared by spiking 10 μL of the above working solutions into 190 μL of blank plasma. The plasma concentrations were in the range of 5.13–513 ng/mL for apigenin, 4.21–421 ng/mL for quercetin, 3.81–381 ng/mL for apigenin-7-O-β-d-glucoside, 3.20–320 ng/mL for quercetin-3-O-β-d-glucoside, 5.13–513 ng/mL for 3′-methoxyluteolin-7-O-β-d-glucoside, 6.02–602 ng/mL for tricin-7-O-β-d-glucopyranoside, respectively. QC samples at low, middle and high concentrations (10.26, 61.56, 461.7 ng/mL for apigenin; 8.42, 50.52, 378.9 ng/mL for quercetin; 7.62, 45.72, 342.9 ng/mL for apigenin-7-O-β-d-glucoside; 6.40, 38.4, 288 ng/mL for quercetin-3-O-β-d-glucoside; 10.26, 61.56, 461.7 ng/mL for 3′-methoxyluteolin-7-O-β-d-glucoside; 12.04, 72.24, 541.8 ng/mL for tricin-7-O-β-d-glucopyranoside) were also prepared by the same operation listed above. All the solutions were kept at 4 °C.

2.6. Sample preparation

A simple liquid–liquid extraction (LLE) method was applied to extract the six flavonoids and IS from rat plasma. To a 50 μL of the rat plasma, 25 μL of IS and 25 μL of 0.1 M hydrochloric acid were added. The mixture was vortexed for 1 min and extracted with 1 mL of dichloromethane by shaking on a vortex mixer for 5 min. The upper layer was transferred to a clean tube after centrifugation at 5000 × g for 5 min and then evaporated to dryness under a gentle stream of nitrogen. The obtained residue was reconstituted in 50 μL of mobile phase and centrifuged at 11,000 × g for 5 min. Subsequently, aliquots of 10 μL were injected into the LC–MS/MS system for analysis.

2.7. Method validation

The method was validated according to the principles of the FDA industry guidance [22,23].

2.7.1. Selectivity

To ensure whether other endogenous components from plasma interfered with the analytes, samples from six different blank rats were analyzed.

2.7.2. Calibration curves and sensitivity

The linearity of each calibration curve was determined by plotting the peak area ratios of analyte:IS vs apigenin, quercetin, apigenin-7-O-β-d-glucoside, quercetin-3-O-β-d-glucoside, 3′-methoxyluteolin-7-O-β-d-glucoside, and tricin-7-O-β-d-glucopyranoside concentrations in rat plasma. The linearity of the calibration curve was determined by linear regression analysis and the acceptable value for correlation coefficient (r) was ≥0.995. Method sensitivity was determined by lower limit of detection (LLOD) and lower limit of quantification (LLOQ) based on a signal-to-noise (S/N) ratio of 3:1 and 5:1, respectively.

2.7.3. Precision and accuracy

Precision and accuracy were investigated by analyzing six replicates of QC samples on the same day (intra-day) and between three different days (inter-day). The intra-day and inter-day precisions were expressed by the relative standard deviation (RSD), and the accuracy was evaluated by comparing the mean calculated concentration as a percentage of the spiked concentration. Acceptance criteria met that accuracy should be less than ±15% and precision be below 15%.

2.7.4. Matrix effect and recovery

The matrix effect of the six analytes and IS was evaluated by analyzing triplicates of plasma samples at three QC levels. Matrix effect was evaluated by comparing corresponding peak areas of plasma extracts spiked with analytes with those of standard solutions.

The extraction efficiency was also investigated by determining triplicates of plasma samples. The extraction recovery was analyzed by comparing the peak areas of plasma extracts spiked with analytes before extraction with those of the post-extraction spiked samples.

2.7.5. Stability

Stability of six analytes in rat plasma was determined by analyzing triplicates of QC samples during the sample processing and storage stage. Samples were stored at ambient temperature for 6 h and at −20 °C for 3 weeks to assess short-term and long-term stability, respectively. Freeze–thaw stability was determined after three freeze–thaw cycles between −20 °C and ambient temperature.

2.8. Pharmacokinetic study

Six male Wistar rats (weighing 220 ± 20 g) were housed under constant temperature (20 ± 2 °C), humidity (50 ± 15%) and lighting (12 h light per day) and were deprived of food for 12 h with water ad libitum before the experiment. The experimental protocols were approved by the Animal Care and Use Committee of Guangdong Medical College (Dongguan, China). Six rats received an intragastric administration of 183 mg/kg P. tomentosa flower extract solution (equivalent to 0.63 mg/kg of apigenin, 1.01 mg/kg of quercetin, 0.33 mg/kg of apigenin-7-O-β-d-glucoside, 0.48 mg/kg of quercetin-3-O-β-d-glucoside, 2.31 mg/kg of 3′-methoxyluteolin-7-O-β-d-glucoside, and 1.67 mg/kg of tricin-7-O-β-d-glucopyranoside). Blood samples (about 250 μL) were collected in heparinized tubes via the jugular veins from each rat at 0, 5, 10, 25, 40 min, and 1, 2, 3, 4, 6, 8, 12 and 24 h after administration, and were immediately centrifuged at 5000 × g for 5 min to collect plasma. The obtained plasma samples were stored at −20 °C until analysis.
Fig. 2. The product ion fragmentation modes and mass spectra of six flavonoids and IS (a, apigenin; b, quercetin; c, apigenin-7-O-β-D-glucoside; d, quercetin-3-O-β-D-glucoside; e, 3′-methoxyluteolin-7-O-β-D-glucoside; f, tricin-7-O-β-D-glucopyranoside; g, IS).
Fig. 3. Representative MRM chromatograms of six flavonoids and IS in plasma. (a) Blank plasma; (b) blank plasma spiked with IS; (c) blank plasma spiked with six analytes at LLOQ and IS; (d) 2.0 h plasma sample after oral administration of *P. tomentosa* flower extract.
3. Results and discussion

3.1. Optimization of LC–MS/MS conditions

Individual analyte solutions were directly infused into the mass spectrometer under the positive and negative ion scan mode. Under the selected ESI condition, all six analytes and IS showed higher sensitivity in the negative mode than in the positive mode, and the most abundant ions are [M–H]− for all analytes. Therefore, the deprotonated form of each compound, the [M–H]− ion, was the parent ion in the Q1 spectra and used as the precursor ion to obtain Q3 product ion spectra. The MS/MS product ion spectra of the analytes and IS are shown in Fig. 2. On the basis of that, to get the maximum response of precursor and product ions, the parameters for fragmentor voltage and collision energy were further optimized. Table 1 shows the optimal fragmentor voltage and collision energy of all the analytes. Finally, the most sensitive mass transition was monitored from m/z 269.1 to 117.2 for apigenin, m/z 301.2 to 151.2 for quercetin, m/z 431.3 to 311.2 for apigenin-7-O-β-D-glucoside, m/z 463.2 to 300.2 for quercetin-3-O-β-D-glucoside, m/z 461.3 to 283.1 for 3′-methoxytaxelotein-7-O-β-D-glucoside, m/z 491.3 to 313.1 for tricin-7-O-β-D-glucopyranoside, and m/z 267.2 to 252.2 for IS.

The peak symmetry of the analytes greatly improved after adding ammonium acetate to the mobile phase. Thus, the concentration of ammonium acetate in aqueous phase was optimized from 1 to 10 mM, and the results showed that adding 2 mM ammonium acetate produced good improvement. In addition, a gradient elution program was used to reduce the retention time and eliminate excessive broadening of the chromatographic peaks. Finally, the optimized gradient elution mentioned in Section 2.2 was adopted.

3.2. Method validation

3.2.1. Selectivity

Selectivity was evaluated by extracting blank plasma from six different sources and comparing the MS/MS responses at the retention times of six analytes to those of the LLOQ level (Fig. 3). No significant peaks were observed in any lane of the blank plasma samples for the six analytes and IS.

3.2.2. Linearity and sensitivity

The calibration curves, correlation coefficients and linear ranges of six analytes in plasma are listed in Table 2. The regression equation of the calibration curve was expressed as Y=aX+b, Y is the peak area ratio of the analyte to IS and X is the corresponding concentration value. All the calibration curves showed good linearity in their corresponding ranges for the six analytes (r > 0.995).

The LLOD and LLOQ obtained using the calculation of the S/N ratio were found to be 3.08 and 5.13 ng/mL for apigenin, 2.53 and 4.21 ng/mL for quercetin, 2.29 and 3.81 ng/mL for apigenin-7-O-β-D-glucoside, 1.92 and 3.20 ng/mL for quercetin-3-O-β-D-glucoside, 3.08 and 5.13 ng/mL for 3′-methoxytaxelotein-7-O-β-D-glucoside, 3.61 and 6.02 ng/mL for tricin-7-O-β-D-glucopyranoside in plasma. The limits were sufficient for pharmacokinetics studies.

3.2.3. Precision and accuracy

The intra-day and inter-day precisions and accuracy are presented in Table 3. The RSD values for intra-day and inter-day precisions were all within 14.0%, whilst the accuracy values were all below 113.8% at each QC level. The results suggested that the present assay showed acceptable accuracy and precision.

3.2.4. Extraction recovery and matrix effect

A single-step LLE with dichloromethane proved to be simple, rapid and acceptable, with a mean extraction efficiency >85% at three QC concentration levels, indicating that the chosen
### Table 1
Summary of the retention times, MS/MS parameters, and precursor and product ions observed for each compound.

| Compound                      | Retention time (min) | Precursor ion (m/z) | Product ion (m/z) | Optimal collision energy (eV) | Optimal fragmentor voltage (V) |
|-------------------------------|----------------------|---------------------|-------------------|-------------------------------|--------------------------------|
| Apigenin                      | 4.43                 | 269.1               | 117.2             | 25                            | 100                            |
| Quercetin                     | 4.21                 | 301.2               | 151.2             | 28                            | 104                            |
| Apigenin-7-O-β-D-glucoside    | 2.80                 | 431.3               | 311.2             | 11                            | 130                            |
| Quercetin-3-O-β-D-glucoside   | 2.94                 | 463.2               | 300.2             | 25                            | 145                            |
| 3'-Methoxyluteolin-7-O-β-D-glucoside | 3.22           | 461.3               | 283.1             | 30                            | 120                            |
| Tricin-7-O-β-D-glucopyranoside | 3.35                 | 491.3               | 313.1             | 25                            | 135                            |
| IS                            | 4.71                 | 267.2               | 252.2             | 25                            | 90                             |

### Table 2
Regression data and LLOQs of six analytes in plasma.

| Compound                      | Range (ng/mL) | Linear regression equation | Correlation coefficient | LLOQ (ng/mL) |
|-------------------------------|---------------|----------------------------|-------------------------|--------------|
| Apigenin                      | 5.13–513      | Y=0.0021X+0.0062           | 0.9962                  | 5.13         |
| Quercetin                     | 4.21–421      | Y=0.0017X+0.0033           | 0.9951                  | 4.21         |
| Apigenin-7-O-β-D-glucoside    | 3.81–381      | Y=0.012X+0.0695           | 0.9987                  | 3.81         |
| Quercetin-3-O-β-D-glucoside   | 3.20–320      | Y=0.035X+0.1021           | 0.9996                  | 3.20         |
| 3'-Methoxyluteolin-7-O-β-D-glucoside | 5.13–513     | Y=0.052X+0.2310          | 0.9951                  | 5.13         |
| Tricin-7-O-β-D-glucopyranoside | 6.02–602      | Y=0.068X+0.8745          | 0.9953                  | 6.02         |

### Table 3
Intra-day, inter-day precision and accuracy of six analytes in plasma (n=6).

| Compound                      | Concentration (ng/mL) | Intra-day Precision (RSD, %) | Intra-day Accuracy (%) | Inter-day Precision (RSD, %) | Inter-day Accuracy (%) |
|-------------------------------|------------------------|------------------------------|------------------------|-------------------------------|------------------------|
| Apigenin                      | 10.26                  | 2.3                          | 107.8                  | 4.7                           | 96.2                   |
| Quercetin                     | 61.56                  | 11.7                         | 95.6                   | 8.6                           | 101.3                  |
|                              | 461.7                  | 6.2                          | 98.7                   | 6.3                           | 102.7                  |
|                              | 8.42                   | 0.7                          | 98.2                   | 2.2                           | 92.5                   |
| Apigenin-7-O-β-D-glucoside    | 50.52                  | 2.7                          | 113.8                  | 3.9                           | 105.6                  |
| Quercetin-3-O-β-D-glucoside   | 378.9                  | 8.1                          | 104.2                  | 4.3                           | 98.9                   |
|                              | 7.62                   | 7.4                          | 97.3                   | 11.1                          | 107.8                  |
| 3'-Methoxyluteolin-7-O-β-D-glucoside | 45.72          | 1.40                         | 92.8                   | 9.6                           | 95.6                   |
|                              | 342.9                  | 5.2                          | 89.8                   | 2.0                           | 96.4                   |
| Tricin-7-O-β-D-glucopyranoside | 38.4                   | 4.2                          | 94.0                   | 8.3                           | 99.6                   |
|                              | 288                    | 9.7                          | 91.6                   | 6.1                           | 93.4                   |

### Table 4
Recoveries, matrix effects and stability of six analytes in plasma (n=3).

| Compound                      | Concentration (ng/mL) | Recovery Average (%) | Recovery RSD (%) | Matrix effect Average (%) | Matrix effect RSD (%) | Short-term stability Remain (%) | Short-term stability RSD (%) | Long-term stability Remain (%) | Long-term stability RSD (%) | Freeze–thaw stability Remain (%) | Freeze–thaw stability RSD (%) |
|-------------------------------|------------------------|----------------------|------------------|--------------------------|----------------------|---------------------------------|-------------------------------|-------------------------------|-------------------------------|---------------------------------|-------------------------------|
| Apigenin                      | 10.26                  | 90.1                 | 6.2              | 96.1                      | 13.0                 | 96.2                            | 6.6                           | 97.6                          | 7.1                           | 114.8                          | 10.2                           |
|                              | 61.56                  | 91.7                 | 8.1              | 98.6                      | 5.7                  | 92.6                            | 3.2                           | 88.2                          | 9.5                           | 98.4                           | 5.7                            |
| Apigenin-7-O-β-D-glucoside    | 461.7                  | 91.7                 | 12.5             | 100.4                     | 10.9                 | 101.8                           | 2.8                           | 103.9                         | 13.6                          | 106.1                          | 4.7                            |
| Quercetin                     | 8.42                   | 90.8                 | 10.7             | 102.7                     | 5.1                  | 105.3                           | 11.2                          | 97.1                          | 5.7                           | 100.0                          | 6.0                            |
| Quercetin-3-O-β-D-glucoside   | 378.9                  | 91.7                 | 7.5              | 97.3                      | 9.5                  | 91.3                            | 4.9                           | 109.5                         | 5.8                           | 94.1                           | 10.1                           |
| 3'-Methoxyluteolin-7-O-β-D-glucoside | 7.62          | 85.1                 | 11.1             | 91.2                      | 11.8                 | 102.2                           | 0.8                           | 112.0                         | 2.2                           | 92.0                           | 9.2                            |
| Tricin-7-O-β-D-glucopyranoside | 45.72                  | 83.2                 | 5.0              | 90.4                      | 9.1                  | 95.6                            | 7.9                           | 90.6                          | 11.0                          | 91.3                           | 3.7                            |
|                              | 342.9                  | 85.0                 | 7.2              | 88.3                      | 7.6                  | 91.1                            | 10.2                          | 101.8                         | 4.7                           | 86.4                           | 5.5                            |
| 3'-Methoxyluteolin-7-O-β-D-glucoside | 38.4           | 84.7                 | 10.0             | 86.7                      | 12.5                 | 87.4                            | 10.4                          | 94.4                          | 3.8                           | 104.6                          | 13.8                           |
| Tricin-7-O-β-D-glucopyranoside | 288                   | 82.7                 | 9.7              | 90.2                      | 10.4                 | 106.7                           | 4.0                           | 93.6                          | 1.7                           | 90.2                           | 9.4                            |
|                              | 12.04                  | 87.1                 | 4.8              | 96.5                      | 9.1                  | 92.6                            | 2.5                           | 110.6                         | 11.3                          | 108.9                          | 8.3                            |
LLE procedure was successful. The extraction recovery at three QC concentrations was 90.1–91.7% for apigenin, 88.9–92.5% for quercetin, 83.2–85.1% for apigenin-7-O-β-D-glucoside, 82.3–84.7% for quercetin-3-O-β-D-glucoside, 84.3–86.6% for 3’-methoxyluteolin-7-O-β-D-glucoside, and 85.2–87.1% for tricin-7-O-β-D-glucopyranoside, respectively (Table 4). The recovery of the IS was 93.0% in rat plasma (n = 3).

The matrix effects of six analytes derived from QC samples were between 86.7% and 103.4%. Under these conditions, the analytes did not exhibit obvious matrix effect.

3.2.5. Stability

The stability results showed that the concentrations of six analytes were between 86.4% and 114.8% of the initial values (Table 4), indicating that all the analytes were stable in rat plasma during the sample processing and storage stage.

3.3. Pharmacokinetics study

The validated LC–MS/MS method was successfully applied to the pharmacokinetic study and simultaneous determination of six flavonoids in rat plasma following intragastric administration of 183 mg extract per kg of body weight. The mean plasma concentration–time profiles of the six flavonoids are presented in Fig. 4, and the main pharmacokinetic parameters calculated by non-compartmental analysis are listed in Table 5. By using the method, we detected the drug concentration in plasma until 24 h after oral administration. The results in this study may be helpful for further investigations on the pharmacokinetics of P. tomentosa flowers, and beneficial for the application of this medicine in preclinical experiments.

4. Conclusions

A selective, sensitive and robust LC–MS/MS method for simultaneous determination of six flavonoids in rat plasma was established. The method employed a simple and rapid extraction procedure for sample preparation, and offered higher sensitivity with little detectable coeluting endogenous substances requiring only 50 μL plasma. This method is proposed for the pharmacokinetic study and preclinical monitoring of P. tomentosa.

Acknowledgments

This work was financially supported by the National Nature Science Foundation of China (No. 81330156), Natural Science Foundation of Guangdong Province of China (No. 2013040016491) and Program for Outstanding Young Teachers in Higher Education Commission of Guangdong Province of China (No. Yq2013085).

References

[1] K Smejkal, S Chudík, P Kloucek, R Marek, J Cvacka, M Urbanová, O Jůlínek, L Kokoska, T Slapetová, P Holubová, A Zima, M Dvorská, J Nat. Prod. 71 (2008) 706–709.
[2] Zhong-Hua-Ben-Cao Editorial Board, ZhonghuaBencao, vol. 20, Shanghai Scientific and Technical Press, Shanghai, 1999, pp. 7338–7359.
[3] Dictionary of Chinese Materia Medica Editorial Board, Zhongyaozadían, Shanghai Scientific and Technical Press, Shanghai, 1985, pp. 1456.
[4] S.K. Kim, S.B. Cho, H.I. Moon, Phytother. Res. 24 (2010) 1898–1900.
[5] K Smejkal, J Sváčková, T Slapetová, K Schneidrová, S Dall’Acqua, G Innocenti, V Závalová, P Kollár, S Chudík, R Marek, O Jůlínek, M Urbanová, M Kartal, M Čišeľ, K Doležal, J Nat. Prod. 23 (2010) 568–572.
[6] J.K. Cho, M.J. Curtis–Long, K.H. Lee, D.W. Kim, H.W. Ryu, H.J. Yulk, K.H. Park, Bioorg. Med. Chem. 21 (2013) 3051–3057.
[7] A. Navrátilová, K. Schneidrová, D. Veselá, Z. Hanáková, A. Fontana, S. Dall’Acqua, J. Cvacka, G. Innocenti, J. Novotná, M. Urbanová, J. Pelleiter, A. Čížek, H. Žemličková, K. Smejkal, Phytochemistry 89 (2013) 104–113.
[8] F.J. Qu, X.Z. Li, M. Yao, L. Yang, H. Chen, J. Gong, S.F. Ni, J. Anhui Agric. Sci. 39 (2011) 19809–19810.
[9] T. Nagata, A. Duval, M. Schmull, T.A. Thernarna, P.R. Crane, Curtis’s Bot. Mag. 30 (2013) 261–274.
[10] S. Damróť, S.R. Jensen, Phytochemistry 34 (1993) 1636–1638.
[11] Y.C. Li, Y.H. Zhao, World J. Integr. Tradit. West. Med. 2 (2007) 451–453.
[12] Y.L. Xing, L.W. Bi, Z.D. Zhao, L.L. Han, T.J. Xia, Chem. Ind. For. Prod. 33 (2013) 135–140.
[13] T. Asai, N. Hara, S. Kobayashi, S. Kohshima, Y. Fujimoto, Phytochemistry 69 (2008) 1234–1241.
[14] A. Zima, J. Hosek, J. Treml, J. Mecislík, P. Suchý, G. Pražanová, A. Lopes, M. Zemlicka, Molecules 15 (2010) 6035–6049.
[15] K. Schneidrová, T. Slapetová, R. Hribal, H. Dvořáková, P. Procházková, J. Novotná, M. Urbanová, J. Cvacka, K. Smejkal, Nat. Prod. Res. 27 (2013) 613–618.
[16] J.K. Cho, Y.B. Ryu, M.J. Curtis–Long, H.W. Ryu, H.J. Yulk, D.W. Kim, H.J. Kim, W.S. Lee, K.H. Park, Bioorg. Med. Chem. 20 (2012) 2595–2602.
[17] P.F. Zhang, C. Li, Zhongguo Zhong Yao Zai Zhi 33 (2008) 2629–2633.
[18] C.H. Li, X.J. Wang, W.Z. Tang, Y.T. Gao, Food Drug 16 (2014) 12–14.
[19] T.F. Jiang, X. Du, Y.P. Shi, Chromatographia 59 (2004) 255–258.
[20] Z.F. Meng, C.X. Dong, D.D. Lv, Chin. J. Spectrosc. Lab. 25 (2008) 273–276.
[21] Z.F. Meng, M.Y. Qiao, Y.M. Liu, J. Zhao, Chem. World 50 (2009) 675–680.
[22] Food and Drug Administration, U.S. Department of Health and Human Services, Guidance for Industry Bioanalytical Method Validation, 2001.
[23] V.P. Shah, K.K. Midha, J.W. Findlay, H.M. Hill, J.D. Hulse, I.J. McGilvery, G. McKay, K.J. Miller, R.N. Patnaila, M.L. Powell, Pharm. Res. 17 (2000) 1551–1557.